Credits Available: 4.50 AMA PRA Category 1 Credit

Description: This curriculum aims to evaluate the landscape of BC management, delving into the latest breakthroughs, therapies, and strategies that have transformed our approach to this complex and chronic condition. This curriculum is designed to offer you a thorough understanding of the wide range of treatment modalities available. From conventional methods to cutting-edge innovations, our goal is to equip you with the insights needed to make informed decisions for optimizing BC management, including use of ADCs, immunotherapy, PARP-inhibitors and a potential therapeutic algorithm for HER 2-low breast cancer.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MBBS, MD, Nurse Practitioner, Physician Assistant, Pharmacist
Target Specialties: Gynecologic Oncology, Oncology

Thomas Grinda

Gustave Roussy
MD

Thomas Grinda, MD, MSc, is a medical oncologist at Gustave Roussy (Villejuif, France) and Assistant Professor of Medicine at Paris-Saclay University (France). He received his medical degree from Sorbonne University (Paris, France) and completed his fellowship at Gustave Roussy and an international fellowship at Dana-Farber Cancer Institute, Harvard Medical School (Boston, USA). His clinical expertise is in breast cancer patients, with a focus on central nervous system metastases and triple-negative breast cancer. Dr. Grinda is a co-principal investigator of the COMPASS-TNBC clinical trial, which aims to develop innovative therapeutic strategies for patients with early relapsed triple-negative breast cancer. Scientifically, he is interested in research on methodology for real-world data (RWD) and is involved in the ESME database of metastatic breast cancer patients in France. He also contributes to the ESMO working group on RWD and digital health.